WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H526799
CAS#: 189224-48-4
Description: KU14R is an imidazoline I(3) receptor antagonist. KU14R selectively blocks the insulin secretory response to imidazolines. KU14R has been shown to block the effects of the atypical I(3) agonist efaroxan at the level of the ATP-sensitive K(+) (K(ATP)) channel in isolated pancreatic islet beta cells. KU14R does not act as an antagonist of either efaroxan or S22068 at an imidazoline site in vivo. Imidazolines are a class of investigational antidiabetic drugs.
Hodoodo Cat#: H526799
Name: KU14R
CAS#: 189224-48-4
Chemical Formula: C13H14N2O
Exact Mass: 214.11
Molecular Weight: 214.268
Elemental Analysis: C, 72.87; H, 6.59; N, 13.07; O, 7.47
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: KU14R; KU-14R; KU 14R.
IUPAC/Chemical Name: 2-(2-ethyl-3H-1-benzofuran-2-yl)-1H-imidazole
InChi Key: JCWVNNMJXQJVNC-UHFFFAOYSA-N
InChi Code: InChI=1S/C13H14N2O/c1-2-13(12-14-7-8-15-12)9-10-5-3-4-6-11(10)16-13/h3-8H,2,9H2,1H3,(H,14,15)
SMILES Code: CCC1(C2=NC=CN2)OC3=C(C=CC=C3)C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 214.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Bleck C, Wienbergen A, Rustenbeck I. Essential role of the imidazoline moiety
in the insulinotropic effect but not the KATP channel-blocking effect of
imidazolines; a comparison of the effects of efaroxan and its imidazole analogue,
KU14R. Diabetologia. 2005 Dec;48(12):2567-75. Epub 2005 Nov 11. PubMed PMID:
16283242.
2: Mayer G, Taberner PV. Effects of the imidazoline ligands efaroxan and KU14R on
blood glucose homeostasis in the mouse. Eur J Pharmacol. 2002 Nov
1;454(1):95-102. PubMed PMID: 12409010.
3: Ball AJ, Flatt PR, McClenaghan NH. Stimulation of insulin secretion in clonal
BRIN-BD11 cells by the imidazoline derivatives KU14r and RX801080. Pharmacol Res.
2000 Dec;42(6):575-9. PubMed PMID: 11058411.
